Abstract
Dexmedetomidine is a sedative agent with limited dosing, safety, and efficacy information in the neonatal population. This comprehensive review describes the available evidence summarizing the use of dexmedetomidine in various neonatal populations. We identified 21 studies and 1 case report supporting the efficacy and short-term safety of DEX in neonates. Reported dosing ranges from 0.5–1.5 mcg/kg/h with or without loading doses. Clinically relevant adverse effects include bradycardia and hypotension. Future studies are needed to determine long-term safety and facilitate clinical applicability.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dexmedetomidine hydrochloride [package insert]. Parmaus (NJ): HQ Specialty Pharma Cooperation; 2015.
Estkowski LM, Morris JL, Sinclair EA. Characterization of dexmedetomidine dosing and safety in neonates and infants. J Pediatr Pharm Ther. 2015;20:112–8.
Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol. 2003;15:263–6.
Ni J, Wei J, Yao Y, Jiang X, Luo L, Luo D. Effect of dexmedetomidine on preventing postoperative agitation in children: a meta-analysis. PLoS One. 2015;10:e0128450.
Tug A, Hanci A, Turk HS, Aybey F, Isil CT, Sayin P, et al. Comparison of two different intranasal doses of dexmedetomidine in children for magnetic resonance imaging sedation. Paediatr Drugs. 2015;17:479–85.
Walker J, Maccallum M, Fischer C, Kopcha R, Saylors R, McCall J. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res. 2006;27:206–10.
Greenberg RG, Wu H, Laughon M, Capparelli E, Rowe S, Zimmerman KO, et al. Population pharmacokinetics of dexmedetomidine in infants. J Clin Pharm. 2017;57:1174–82.
McPherson C, Ortinau CM, Vesoulis Z. Practical approaches to sedation and analgesia in the newborn. J Perinatol. 2021;41:383–95.
Puia-Dumitrescu M, Comstock BA, Li S, Heagerty PJ, Perez KM, Law JB, et al. Assessment of 2-year neurodevelopmental outcomes in extremely preterm infants receiving opioids and benzodiazepines. JAMA Netw Open. 2021;4:e2115998.
Durrmeyer X, Vutskits L, Anand KJS, Rimensberger PC. Use of analgesic and sedative drugs in the NICU: integrating clinical trials and laboratory data. Pediatr Res. 2010;67:117–27.
Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database Syst Rev. 2017;1:CD002052.
O’Mara K, Gal P, Wimmer J, Ransom JL, Carlos RQ, Dimagulia MAVT, et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharm Ther. 2012;17:252–62.
Chrysostomou C, Schulman SR, Herrera Castellanos M, Cofer BE, Mitra S, Garcia da Rocha M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2014;164:276–82.
Dersch-Mills DA, Banasch HL, Yusuf K, Howlett A. Dexmedetomidine use in a tertiary care NICU: a descriptive study. Ann Pharmacother. 2019;53:464–70.
van Dijkman SC, De Cock PAJG, Smets K, Decaluwe W, Smits A, Allegaert K, et al. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated newborns: impact of design optimisation. Eur J Clin Pharm. 2019;75:1393–404.
McAdams RM, Pak D, Lalovic B, Phillips B, Shen DD. Dexmedetomidine pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. Anesthesiol Res. 2020;2582965.
Gundersen JK, Chakkarapani E, Jary S, Menassa DA, Scull-Brown E, Frymoyer A, et al. Morphine and fentanyl exposure during therapeutic hypothermia does not impair neurodevelopment. EClinicalMedicine. 2021;36:100892.
O’Mara K, Weiss MD. Dexmedetomidine for sedation of neonates with HIE undergoing therapeutic hypothermia: a single-center experience. AJP Rep. 2018;8:e168–e173.
Cosnahan AS, Angert RM, Jano E, Wachtel EV. Dexmedetomidine versus intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia. J Perinatol. 2021;41:2284–91.
Elliott M, Burnsed J, Heinan K, Letzkus L, Andris R, Fairchild K, et al. Effect of dexmedetomidine on heart rate in neonates with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia. J Neonatal Perinat Med. 2021;15:47–54. https://doi.org/10.3233/NPM-210737.
Dilek O, Yasemin G, Atci M. Preliminary experience with dexmedetomidine in neonatal anesthesia. J Anaesthesiol Clin Pharm. 2011;27:17–22.
Waurick K, Sauerland C, Goeters C. Dexmedetomidine sedation combined with caudal anesthesia for lower abdominal and extremity surgery in ex-preterm and full-term infants. Paediatr Anaesth. 2017;27:637–42.
Bong CL, Yeo ASH, Fabila T, Tan JS. A pilot study of dexmedetomidine sedation and caudal anesthesia for inguinal hernia repair in infants. Paediatr Anaesth. 2016;26:621–7.
Bong CL, Tan J, Lim S, Low Y, Sim SW, Rajadurai VS, et al. Randomised controlled trial of dexmedetomidine sedation vs general anaesthesia for inguinal hernia surgery on perioperative outcomes in infants. Br J Anaesth. 2019;122:662–70.
Zuppa AF, Nicolson SC, Wilder NS, Ibla JC, Gottlieb EA, Burns KM, et al. Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. Br J Anaesth. 2019;123:839–52.
Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, et al. Dexmedetomidine pharmacokinetics and a new dosing paradigm in infants supported with cardiopulmonary bypass. Anesth Analg. 2019;129:1519–28.
Lam F, Bhutta AT, Tobias JD, Gossett JM, Morales L, Gupta P. Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease. Pediatr Cardiol. 2012;33:1069–77.
Su F, Gastonguay MR, Nicolson SC, DiLiberto M, Ocampo-Pelland A, Zuppa AF. Dexmedetomidine pharmacology in neonates and infants after open heart surgery. Anesth Analg. 2016;122:1556–66.
Sellas MN, Kyllonen KC, Lepak MR, Rodriguez RJ. Dexmedetomidine for the management of postoperative pain and sedation in newborns. J Pediatr Pharm Ther. 2019;24:227–33.
Sykes AG, Oviedo P, Rooney A, Gollin G. An assessment of dexmedetomidine as an opioid-sparing agent after neonatal open thoracic and abdominal operations. J Perinatol. 2021. https://doi.org/10.1038/s41372-021-01175-7.
Bua J, Massaro M, Cossovel F, Monasta L, Brovendani P, Cozzi G, et al. Intranasal dexmedetomidine, as midazolam-sparing drug, for MRI in preterm neonates. Paediatr Anaesth. 2018;28:747–8.
Dexmedetomidine. In: Specific Lexicomp Online Database [database on the Internet]. Hudson (OH): Lexicomp Inc.: 2021 [updated 29 July 2021; cited 27 July 2021]. Available from: http://online.lexi.com. Subscription required to view.
Nakano T, Okamoto H. Dexmedetomidine-induced cerebral hypoperfusion exacerbates ischemic brain injury in rats. J Anesth. 2009;23:378–84.
Kubota T, Fukasawa T, Kitamura E, Magota M, Kato Y, Natsume J, et al. Epileptic seizures induced by dexmedetomidine in a neonate. Brain Dev. 2013;35:360–2.
Endesfelder S, Makki H, von Haefen C, Spies CD, Bührer C, Sifringer M. Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain. PLoS One. 2017;12:e0171498.
Tachibana K, Hashimoto T, Kato R, Uchida Y, Ito R, Takita K, et al. Neonatal administration with dexmedetomidine does not impair the rat hippocampal synaptic plasticity later in adulthood. Paediatr Anaesth. 2012;22:713–9.
Zhang Y, Gao Q, Wu Z, Xue H, Liu B, Zhao P. Dexmedetomidine promotes hippocampal neurogenesis and improves spatial learning and memory in neonatal rats. Drug Des Devel Ther. 2019;13:4439–49.
Lee MM, Caylor K, Gockenbach N. Evaluating the transition from dexmedetomidine to clonidine for the prevention of withdrawal in critically ill pediatric patients. J Pediatr Pharm Ther. 2020;25:104–10.
Gagnon DJ, Riker RR, Glisic EK, Kelner A, Perrey HM, Fraser GL. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy. 2015;35:251–9.
Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71:1500–8.
Campos-Beata Y, Saavedra-Mitjans M, Garin N, Cardenete J, Cardona D, Riera P. Physicochemical compatibility of dexmedetomidine with parenteral nutrition. Nutr Clin Pr. 2020;35:967–72.
Baserga M, DuPont TL, Ostrander B, Minton S, Sheffield M, Balch AH, et al. Dexmedetomidine use in infants undergoing cooling due to neonatal encephalopathy (DICE Trial): a randomized controlled trial: background, aims and study protocol. Front Pain Res. 2021;2:770511.
Author information
Authors and Affiliations
Contributions
DM and PS conceived the presented idea. DM completed original literature search and methodology. All authors contributed to analyzing literature, synthesizing results, and writing manuscripts. All authors agree to the final manuscript version.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
This study was performed in accordance with the Declaration of Helsinki.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
McDonald, D., Palsgraf, H. & Shah, P. Dexmedetomidine – An emerging option for sedation in neonatal patients. J Perinatol 42, 845–855 (2022). https://doi.org/10.1038/s41372-022-01351-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-022-01351-3